NCT07816692 iDose TR Administration in an Office-Based Surgery Setting
| NCT ID | NCT07816692 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Glaukos Corporation |
| Condition | Open Angle Glaucoma (OAG) |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2026-05-13 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2026-05-13 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinical in-use observational trial to evaluate the administration of iDose TR (travoprost intracameral implant) in an office-based surgery setting.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Open angle glaucoma (OAG) or ocular hypertension (OHT) Exclusion Criteria: * Prior administration of iDose TR or administration of an investigational intracameral implant in the study eye Active ocular infection or inflammation History of hypersensitivity to travoprost or implant components Recent ocular surgery Uncontrolled systemic disease Any condition preventing safe implantation
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07816692 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Open Angle Glaucoma (OAG). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07816692 currently recruiting?
Yes, NCT07816692 is actively recruiting participants. Contact the research team at ClinicalResearch@glaukos.com for enrollment information.
Where is the NCT07816692 trial being conducted?
This trial is being conducted at Austin, United States.
Who is sponsoring the NCT07816692 clinical trial?
NCT07816692 is sponsored by Glaukos Corporation. The trial plans to enroll 30 participants.